Aspirin use does not affect benefit of apixaban over warfarin in stroke prevention in AFLiterature - Alexander et al. Eur Heart J. 2013 - Eur Heart J. 2013 Oct 20
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Alexander JH, Lopes RD, Thomas L et al.
Eur Heart J. 2013 Oct 20. [Epub ahead of print]
BackgroundOral anticoagulants have been shown to be more effective for stroke prevention than antiplatelet therapy with aspirin alone (1,2] or aspirin plus clopidogrel  in patients with atrial fibrillation (AF). Patients with AF commonly also have coronary artery disease or other indications for aspirin [4,5].
High rates of bleeding have been observed with the combination of aspirin therapy and vitamin K antagonists (VKAs)[6-12]. Also in patients with recent acute coronary syndromes who were already on antiplatelet therapy, more bleedings were seen in patients receiving new oral anticoagulants as compared to placebo [13,14]. Based on these observations, it is recommended to combine antiplatelet and anticoagulant therapy for up to 12 months in patients with AF and a coronary stent and to then discontinue antiplatelet therapy [15-17].
The ARISTOTLE trial demonstrated superior efficacy of apixaban over warfarin in the prevention of stroke in patients with AF, and apixaban resulted in fewer major bleedings . This analysis of the ARISTOTLE trial studied the efficacy and safety of apixaban compared with warfarin in patients receiving concomitant low-dose aspirin.
- Similar stroke reductions were seen with apixaban as compared to warfarin in aspirin users (1.12% vs. 1.91%, HR: 0.58, 95%CI: 0.39-0.85) and non-users (1.11% vs. 1.32%, HR: 0.84, 95%CI: 0.66-1.07, P for treatment interaction= 0.10). No effects of aspirin use on the effect of apixaban vs. warfarin on the rate of ischaemic stroke, myocardial infarction or death were seen.
- Apixaban resulted in consistent reductions in bleeding as compared to warfarin, in aspirin users (3.10% vs. 3.92% with warfarin, HR: 0.77, 95%CI: 0.60-0.99) and non-users (1.82% vs. 2.78%, HR: 0.65, 95%CI: 0.55-0.78, P for interaction: 0.29). Similarly, consistent benefits were seen with apixaban compared with warfarin among aspirin users and non-users for haemorrhagic stroke, major or clinically relevant non-major bleeding and any bleeding.
- Similar results were seen in analyses that accounted for whether a patient was taking aspirin at the time of bleeding.
- Correction for the propensity to use aspirin for differences in prognostically important baseline variables associated with aspirin use, aspirin users had similar outcome rates as compared to non-users. Only upon further correction for post-randomisation variables assoaciated with aspirin use, aspirin users tended to have higher rates of stroke or systemic embolism, ischaemic stroke and myocardial infarction.
ConclusionThis analysis of the ARISTOTLE trial demonstrates that the benefit of apixaban over warfarin in reduction stroke or systemic embolism in patients with AF is not affected by concomitant aspirin use. If there is a strong indication for simultaneous treatment with aspirin and oral anticoagulation, apixaban seems to be a safer option than warfarin.
Since in this study aspirin use was not blinded, nor randomised, further randomised clinical trials need to better define the optimal antithrombotic regimen and its duration in patients with both AF and an indication for antiplatelet therapy.
Find this article on Pubmed
1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857–867.
2. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118:2029–2037.
3. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903–1912.
4. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120:2271–2306.
5. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update on the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:645–681.
6. Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241–250.
7. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006;27:519–526.
8. Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet warfarin therapy after coronary stenting. Eur Heart J 2007;28:726–732.
9. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433–1441.
10. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969–974.
11. van Es RF, Jonker JJ, Verheugt FW, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomized controlled trial. Lancet 2002;360:109–113.
12. Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 2007;167:117–124.
13. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9–19.
14. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365: 699–708.
15. Faxon DP, Eikelboom JW, Berger PB et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting.A North-American perspective. Thromb Haemost 2011;106:572–584.
16. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010;103:13–28.
17. You JJ, Singer DE, Howard PA et al. Antithrombotic therapy for atrial fibrillation, antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012;141:e531S–75S.
18. Granger CB, Alexander JH, McMurray JV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 981–992.